Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pricing In ‘Exceptional’ Times: ICER Aims To Shape US Policy For Novel COVID Drugs, Vaccines

Jul 05 2020

• By Cathy Kelly

Microscopic cells of Coronavirus — Consensus On Payment Models Needed

Related Content

Gilead’s Remdesivir Pricing Sets ‘Promising’ Precedent For Future COVID-19 Drugs

Jun 30 2020

Patent “March-In” As Price Control Draw Little Support At US National Academies Meeting

Aug 21 2019

Louisiana Subscription Contract For Generic Epclusa About Access, Not Discounts

Aug 08 2019

NIH Reluctant To “March In”: Collins Suggests Authority Not Intended To Address Pricing Concerns

Apr 20 2016

Additional Topics

United States Reimbursement Pricing Strategies Coronavirus COVID-19 Health Technology Assessment Policy BioPharmaceutical

More from Market Access

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window